Urea cycle disorders in Spain: an observational, cross-sectional and multicentric study of 104 cases
Background Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain. Methods Observational, cross-sectional and multicenter study. Clinical, b...
Saved in:
| Published in | Orphanet journal of rare diseases Vol. 9; no. 1; p. 187 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
30.11.2014
BioMed Central Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1750-1172 1750-1172 |
| DOI | 10.1186/s13023-014-0187-4 |
Cover
| Abstract | Background
Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain.
Methods
Observational, cross-sectional and multicenter study. Clinical, biochemical and genetic data were collected from patients with UCDs, treated in the metabolic diseases centers in Spain between February 2012 and February 2013, covering the entire Spanish population. Heterozygous mothers of patients with OTC deficiency were only included if they were on treatment due to being symptomatic or having biochemistry abnormalities.
Results
104 patients from 98 families were included. Ornithine transcarbamylase deficiency was the most frequent condition (64.4%) (61.2% female) followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria (9.6%). Only 13 patients (12.5%) were diagnosed in a pre-symptomatic state. 63% of the cases presented with type intoxication encephalopathy. The median ammonia level at onset was 298 μmol/L (169-615). The genotype of 75 patients is known, with 18 new mutations having been described. During the data collection period four patients died, three of them in the early days of life. The median current age is 9.96 years (5.29-18), with 25 patients over 18 years of age. Anthropometric data, expressed as median and z-score for the Spanish population is shown. 52.5% of the cases present neurological sequelae, which have been linked to the type of disease, neonatal onset, hepatic failure at diagnosis and ammonia values at diagnosis. 93 patients are following a protein restrictive diet, 0.84 g/kg/day (0.67-1.10), 50 are receiving essential amino acid supplements, 0.25 g/kg/day (0.20-0.45), 58 arginine, 156 mg/kg/day (109-305) and 45 citrulline, 150 mg/kg/day (105-199). 65 patients are being treated with drugs: 4 with sodium benzoate, 50 with sodium phenylbutyrate, 10 with both drugs and 1 with carglumic acid.
Conclusions
Studies like this make it possible to analyze the frequency, natural history and clinical practices in the area of rare diseases, with the purpose of knowing the needs of the patients and thus planning their care. |
|---|---|
| AbstractList | Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain.
Observational, cross-sectional and multicenter study. Clinical, biochemical and genetic data were collected from patients with UCDs, treated in the metabolic diseases centers in Spain between February 2012 and February 2013, covering the entire Spanish population. Heterozygous mothers of patients with OTC deficiency were only included if they were on treatment due to being symptomatic or having biochemistry abnormalities.
104 patients from 98 families were included. Ornithine transcarbamylase deficiency was the most frequent condition (64.4%) (61.2% female) followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria (9.6%). Only 13 patients (12.5%) were diagnosed in a pre-symptomatic state. 63% of the cases presented with type intoxication encephalopathy. The median ammonia level at onset was 298 μmol/L (169-615). The genotype of 75 patients is known, with 18 new mutations having been described. During the data collection period four patients died, three of them in the early days of life. The median current age is 9.96 years (5.29-18), with 25 patients over 18 years of age. Anthropometric data, expressed as median and z-score for the Spanish population is shown. 52.5% of the cases present neurological sequelae, which have been linked to the type of disease, neonatal onset, hepatic failure at diagnosis and ammonia values at diagnosis. 93 patients are following a protein restrictive diet, 0.84 g/kg/day (0.67-1.10), 50 are receiving essential amino acid supplements, 0.25 g/kg/day (0.20-0.45), 58 arginine, 156 mg/kg/day (109-305) and 45 citrulline, 150 mg/kg/day (105-199). 65 patients are being treated with drugs: 4 with sodium benzoate, 50 with sodium phenylbutyrate, 10 with both drugs and 1 with carglumic acid.
Studies like this make it possible to analyze the frequency, natural history and clinical practices in the area of rare diseases, with the purpose of knowing the needs of the patients and thus planning their care. Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain.BACKGROUNDAdvances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain.Observational, cross-sectional and multicenter study. Clinical, biochemical and genetic data were collected from patients with UCDs, treated in the metabolic diseases centers in Spain between February 2012 and February 2013, covering the entire Spanish population. Heterozygous mothers of patients with OTC deficiency were only included if they were on treatment due to being symptomatic or having biochemistry abnormalities.METHODSObservational, cross-sectional and multicenter study. Clinical, biochemical and genetic data were collected from patients with UCDs, treated in the metabolic diseases centers in Spain between February 2012 and February 2013, covering the entire Spanish population. Heterozygous mothers of patients with OTC deficiency were only included if they were on treatment due to being symptomatic or having biochemistry abnormalities.104 patients from 98 families were included. Ornithine transcarbamylase deficiency was the most frequent condition (64.4%) (61.2% female) followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria (9.6%). Only 13 patients (12.5%) were diagnosed in a pre-symptomatic state. 63% of the cases presented with type intoxication encephalopathy. The median ammonia level at onset was 298 μmol/L (169-615). The genotype of 75 patients is known, with 18 new mutations having been described. During the data collection period four patients died, three of them in the early days of life. The median current age is 9.96 years (5.29-18), with 25 patients over 18 years of age. Anthropometric data, expressed as median and z-score for the Spanish population is shown. 52.5% of the cases present neurological sequelae, which have been linked to the type of disease, neonatal onset, hepatic failure at diagnosis and ammonia values at diagnosis. 93 patients are following a protein restrictive diet, 0.84 g/kg/day (0.67-1.10), 50 are receiving essential amino acid supplements, 0.25 g/kg/day (0.20-0.45), 58 arginine, 156 mg/kg/day (109-305) and 45 citrulline, 150 mg/kg/day (105-199). 65 patients are being treated with drugs: 4 with sodium benzoate, 50 with sodium phenylbutyrate, 10 with both drugs and 1 with carglumic acid.RESULTS104 patients from 98 families were included. Ornithine transcarbamylase deficiency was the most frequent condition (64.4%) (61.2% female) followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria (9.6%). Only 13 patients (12.5%) were diagnosed in a pre-symptomatic state. 63% of the cases presented with type intoxication encephalopathy. The median ammonia level at onset was 298 μmol/L (169-615). The genotype of 75 patients is known, with 18 new mutations having been described. During the data collection period four patients died, three of them in the early days of life. The median current age is 9.96 years (5.29-18), with 25 patients over 18 years of age. Anthropometric data, expressed as median and z-score for the Spanish population is shown. 52.5% of the cases present neurological sequelae, which have been linked to the type of disease, neonatal onset, hepatic failure at diagnosis and ammonia values at diagnosis. 93 patients are following a protein restrictive diet, 0.84 g/kg/day (0.67-1.10), 50 are receiving essential amino acid supplements, 0.25 g/kg/day (0.20-0.45), 58 arginine, 156 mg/kg/day (109-305) and 45 citrulline, 150 mg/kg/day (105-199). 65 patients are being treated with drugs: 4 with sodium benzoate, 50 with sodium phenylbutyrate, 10 with both drugs and 1 with carglumic acid.Studies like this make it possible to analyze the frequency, natural history and clinical practices in the area of rare diseases, with the purpose of knowing the needs of the patients and thus planning their care.CONCLUSIONSStudies like this make it possible to analyze the frequency, natural history and clinical practices in the area of rare diseases, with the purpose of knowing the needs of the patients and thus planning their care. Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain. Observational, cross-sectional and multicenter study. Clinical, biochemical and genetic data were collected from patients with UCDs, treated in the metabolic diseases centers in Spain between February 2012 and February 2013, covering the entire Spanish population. Heterozygous mothers of patients with OTC deficiency were only included if they were on treatment due to being symptomatic or having biochemistry abnormalities. 104 patients from 98 families were included. Ornithine transcarbamylase deficiency was the most frequent condition (64.4%) (61.2% female) followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria (9.6%). Only 13 patients (12.5%) were diagnosed in a pre-symptomatic state. 63% of the cases presented with type intoxication encephalopathy. The median ammonia level at onset was 298 [mu]mol/L (169-615). The genotype of 75 patients is known, with 18 new mutations having been described. During the data collection period four patients died, three of them in the early days of life. The median current age is 9.96 years (5.29-18), with 25 patients over 18 years of age. Anthropometric data, expressed as median and z-score for the Spanish population is shown. 52.5% of the cases present neurological sequelae, which have been linked to the type of disease, neonatal onset, hepatic failure at diagnosis and ammonia values at diagnosis. 93 patients are following a protein restrictive diet, 0.84 g/kg/day (0.67-1.10), 50 are receiving essential amino acid supplements, 0.25 g/kg/day (0.20-0.45), 58 arginine, 156 mg/kg/day (109-305) and 45 citrulline, 150 mg/kg/day (105-199). 65 patients are being treated with drugs: 4 with sodium benzoate, 50 with sodium phenylbutyrate, 10 with both drugs and 1 with carglumic acid. Studies like this make it possible to analyze the frequency, natural history and clinical practices in the area of rare diseases, with the purpose of knowing the needs of the patients and thus planning their care. Background Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain. Methods Observational, cross-sectional and multicenter study. Clinical, biochemical and genetic data were collected from patients with UCDs, treated in the metabolic diseases centers in Spain between February 2012 and February 2013, covering the entire Spanish population. Heterozygous mothers of patients with OTC deficiency were only included if they were on treatment due to being symptomatic or having biochemistry abnormalities. Results 104 patients from 98 families were included. Ornithine transcarbamylase deficiency was the most frequent condition (64.4%) (61.2% female) followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria (9.6%). Only 13 patients (12.5%) were diagnosed in a pre-symptomatic state. 63% of the cases presented with type intoxication encephalopathy. The median ammonia level at onset was 298 [mu]mol/L (169-615). The genotype of 75 patients is known, with 18 new mutations having been described. During the data collection period four patients died, three of them in the early days of life. The median current age is 9.96 years (5.29-18), with 25 patients over 18 years of age. Anthropometric data, expressed as median and z-score for the Spanish population is shown. 52.5% of the cases present neurological sequelae, which have been linked to the type of disease, neonatal onset, hepatic failure at diagnosis and ammonia values at diagnosis. 93 patients are following a protein restrictive diet, 0.84 g/kg/day (0.67-1.10), 50 are receiving essential amino acid supplements, 0.25 g/kg/day (0.20-0.45), 58 arginine, 156 mg/kg/day (109-305) and 45 citrulline, 150 mg/kg/day (105-199). 65 patients are being treated with drugs: 4 with sodium benzoate, 50 with sodium phenylbutyrate, 10 with both drugs and 1 with carglumic acid. Conclusions Studies like this make it possible to analyze the frequency, natural history and clinical practices in the area of rare diseases, with the purpose of knowing the needs of the patients and thus planning their care. Keywords: Urea cycle disorders, UCDs, N-acetylglutamate synthase, Carbamoylphosphate synthetase 1, Ornithine transcarbamylase, Argininosuccinate synthetase, Citrullinemia type 1, Argininosuccinate lyase, Argininosuccinic aciduria, Arginase 1 Background Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain. Methods Observational, cross-sectional and multicenter study. Clinical, biochemical and genetic data were collected from patients with UCDs, treated in the metabolic diseases centers in Spain between February 2012 and February 2013, covering the entire Spanish population. Heterozygous mothers of patients with OTC deficiency were only included if they were on treatment due to being symptomatic or having biochemistry abnormalities. Results 104 patients from 98 families were included. Ornithine transcarbamylase deficiency was the most frequent condition (64.4%) (61.2% female) followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria (9.6%). Only 13 patients (12.5%) were diagnosed in a pre-symptomatic state. 63% of the cases presented with type intoxication encephalopathy. The median ammonia level at onset was 298 μmol/L (169-615). The genotype of 75 patients is known, with 18 new mutations having been described. During the data collection period four patients died, three of them in the early days of life. The median current age is 9.96 years (5.29-18), with 25 patients over 18 years of age. Anthropometric data, expressed as median and z-score for the Spanish population is shown. 52.5% of the cases present neurological sequelae, which have been linked to the type of disease, neonatal onset, hepatic failure at diagnosis and ammonia values at diagnosis. 93 patients are following a protein restrictive diet, 0.84 g/kg/day (0.67-1.10), 50 are receiving essential amino acid supplements, 0.25 g/kg/day (0.20-0.45), 58 arginine, 156 mg/kg/day (109-305) and 45 citrulline, 150 mg/kg/day (105-199). 65 patients are being treated with drugs: 4 with sodium benzoate, 50 with sodium phenylbutyrate, 10 with both drugs and 1 with carglumic acid. Conclusions Studies like this make it possible to analyze the frequency, natural history and clinical practices in the area of rare diseases, with the purpose of knowing the needs of the patients and thus planning their care. |
| ArticleNumber | 187 |
| Audience | Academic |
| Author | Quijada-Fraile, Pilar Martín-Hernández, Elena Castejón-Ponce, Esperanza Martínez-Pardo, Mercedes Pérez-Cerdá, Celia Aldámiz-Echevarría, Luis Balmaseda-Serrano, Elena Pintos-Morell, Guillem García-Jiménez, Inmaculada Vives-Piñera, Inmaculada Dalmau, Jaime Couce, María Luz Meavilla, Silvia Serrano-Nieto, Juliana Bueno-Delgado, María Amor Ruiz-Pons, Mónica Bélanger-Quintana, Amaya Lama-More, Rosa A Moráis, Ana Pedrón-Giner, Consuelo Peña-Quintana, Luis J Sierra-Córcoles, Concepción Sanjurjo-Crespo, Pablo García-Silva, María Teresa del Toro-Riera, Mirella Vitoria-Miñana, Isidro |
| Author_xml | – sequence: 1 givenname: Elena surname: Martín-Hernández fullname: Martín-Hernández, Elena email: emartinhernandez@salud.madrid.org organization: Pediatric Rares Diseases Unit, Metabolic and Mitochondrial Diseases, Pediatric Department, Hospital Universitario 12 de Octubre. Research Institute (i +12), Madrid, Spain – sequence: 2 givenname: Luis surname: Aldámiz-Echevarría fullname: Aldámiz-Echevarría, Luis organization: H.U. de Cruces – sequence: 3 givenname: Esperanza surname: Castejón-Ponce fullname: Castejón-Ponce, Esperanza organization: H. Sant Joan de Déu – sequence: 4 givenname: Consuelo surname: Pedrón-Giner fullname: Pedrón-Giner, Consuelo organization: H.U. Infantil del Niño Jesús – sequence: 5 givenname: María Luz surname: Couce fullname: Couce, María Luz organization: C.H.U. de Santiago – sequence: 6 givenname: Juliana surname: Serrano-Nieto fullname: Serrano-Nieto, Juliana organization: H. Materno Infantil Carlos Haya – sequence: 7 givenname: Guillem surname: Pintos-Morell fullname: Pintos-Morell, Guillem organization: H.U. Germans Trias i Pujol – sequence: 8 givenname: Amaya surname: Bélanger-Quintana fullname: Bélanger-Quintana, Amaya organization: H.U. Ramón y Cajal – sequence: 9 givenname: Mercedes surname: Martínez-Pardo fullname: Martínez-Pardo, Mercedes organization: H.U. Ramón y Cajal – sequence: 10 givenname: María Teresa surname: García-Silva fullname: García-Silva, María Teresa organization: Pediatric Rares Diseases Unit, Metabolic and Mitochondrial Diseases, Pediatric Department, Hospital Universitario 12 de Octubre. Research Institute (i +12), Madrid, Spain – sequence: 11 givenname: Pilar surname: Quijada-Fraile fullname: Quijada-Fraile, Pilar organization: Pediatric Rares Diseases Unit, Metabolic and Mitochondrial Diseases, Pediatric Department, Hospital Universitario 12 de Octubre. Research Institute (i +12), Madrid, Spain – sequence: 12 givenname: Isidro surname: Vitoria-Miñana fullname: Vitoria-Miñana, Isidro organization: H. Infantil La Fe – sequence: 13 givenname: Jaime surname: Dalmau fullname: Dalmau, Jaime organization: H. Infantil La Fe – sequence: 14 givenname: Rosa A surname: Lama-More fullname: Lama-More, Rosa A organization: H.U. La Paz – sequence: 15 givenname: María Amor surname: Bueno-Delgado fullname: Bueno-Delgado, María Amor organization: H.U. Virgen del Rocío – sequence: 16 givenname: Mirella surname: del Toro-Riera fullname: del Toro-Riera, Mirella organization: H. Vall d’Hebrón – sequence: 17 givenname: Inmaculada surname: García-Jiménez fullname: García-Jiménez, Inmaculada organization: H.U. Miguel Servet – sequence: 18 givenname: Concepción surname: Sierra-Córcoles fullname: Sierra-Córcoles, Concepción organization: C.H. de Jaén – sequence: 19 givenname: Mónica surname: Ruiz-Pons fullname: Ruiz-Pons, Mónica organization: H.U. Ntra. Sra. de la Candelaria – sequence: 20 givenname: Luis J surname: Peña-Quintana fullname: Peña-Quintana, Luis J organization: H.U. Materno Infantil de Las Palmas – sequence: 21 givenname: Inmaculada surname: Vives-Piñera fullname: Vives-Piñera, Inmaculada organization: H.C.U. Virgen de la Arrixaca – sequence: 22 givenname: Ana surname: Moráis fullname: Moráis, Ana organization: H.U. La Paz – sequence: 23 givenname: Elena surname: Balmaseda-Serrano fullname: Balmaseda-Serrano, Elena organization: C.H.U. de Albacete – sequence: 24 givenname: Silvia surname: Meavilla fullname: Meavilla, Silvia organization: H. Sant Joan de Déu – sequence: 25 givenname: Pablo surname: Sanjurjo-Crespo fullname: Sanjurjo-Crespo, Pablo organization: H.U. de Cruces – sequence: 26 givenname: Celia surname: Pérez-Cerdá fullname: Pérez-Cerdá, Celia organization: CEDEM. Facultad de Ciencias, Universidad Autónoma de Madrid |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25433810$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1rFDEUhoNU7If-AG8k4I2CU_M1yYwXQil-FAqCtdchm5ysKbPJmswU99-b3amlK9KEkJA878k5nPcYHcQUAaGXlJxS2sn3hXLCeEOoqKtTjXiCjqhqSUOpYgcPzofouJQbQkTLSfcMHbJWcN5RcoTcdQaD7cYOgF0oKTvIBYeIr9YmxA_YRJwWBfKtGUOKZniHbU6lNAXsfFEJh1fTMAYLcczB4jJOboOTx5QIbE2B8hw99WYo8OJuP0HXnz_9OP_aXH77cnF-dtlYSfqxsTU54Y00UnXELqxrSe97CrwTSsreSwc9KMesWVhpved1EGEl651nnVf8BH2c466nxQrcLiEz6HUOK5M3Opmg919i-KmX6VYL1nZM8hrgzV2AnH5NUEa9CsXCMJgIaSqaSqW4Ukyyir6e0aUZQIfoU41ot7g-awWRoueyr9Tpf6g6HayCrd30od7vCd7uCSozwu9xaaZS9MXV93321cNy7-v8290K0BnY9SyDv0co0VsH6dlBujpIbx2kRdWofzQ2jLvm18zD8KiSzcpSf4lLyPomTblapDwi-gNC6djJ |
| CitedBy_id | crossref_primary_10_1186_s13052_024_01740_8 crossref_primary_10_1007_s10545_018_0157_4 crossref_primary_10_1159_000508679 crossref_primary_10_1172_jci_insight_132342 crossref_primary_10_3390_pediatric12030019 crossref_primary_10_1111_pan_13905 crossref_primary_10_1111_jcpt_12593 crossref_primary_10_1016_j_ymgmr_2020_100605 crossref_primary_10_3390_jcm11175045 crossref_primary_10_3390_nu14132755 crossref_primary_10_1016_j_ymgmr_2021_100724 crossref_primary_10_1177_2326409818813177 crossref_primary_10_1002_jimd_12146 crossref_primary_10_1002_jimd_12403 crossref_primary_10_1016_j_ymgmr_2020_100619 crossref_primary_10_1016_j_jpba_2019_112798 crossref_primary_10_3390_ijns6040077 crossref_primary_10_1007_s10545_017_0088_5 crossref_primary_10_1186_s13023_020_01606_2 crossref_primary_10_1186_s13023_025_03624_4 crossref_primary_10_1177_1971400917715880 crossref_primary_10_1016_j_gene_2018_09_026 crossref_primary_10_3390_ijns10020028 crossref_primary_10_3389_fgene_2022_952467 crossref_primary_10_1016_j_ymgme_2019_07_009 crossref_primary_10_1002_jimd_12384 crossref_primary_10_1016_j_revmed_2016_02_011 crossref_primary_10_1002_jimd_12100 crossref_primary_10_1016_j_ymgme_2019_07_004 |
| Cites_doi | 10.1016/j.ymgme.2009.06.011 10.1093/ndt/14.4.910 10.1023/A:1012726207870 10.1007/s00439-002-0686-6 10.1006/mgme.2001.3221 10.1172/JCI111640 10.1002/humu.9011 10.1023/A:1005353407220 10.1016/j.ymgme.2013.07.008 10.1111/j.1399-3046.2009.01228.x 10.1136/adc.2005.091637 10.1007/s004670100702 10.1111/j.1651-2227.2008.00952.x 10.1186/1750-1172-7-32 10.1007/s00431-003-1177-z 10.1016/j.anpedi.2008.10.007 10.1067/mpd.2001.111830 10.1007/s10545-007-0718-4 10.1007/s10545-010-9151-1 10.1056/NEJMoa066596 10.1053/siny.2001.0083 10.1007/s00431-002-1126-2 10.1007/978-3-642-15720-2_20 10.1067/mpd.2002.122394 10.1111/petr.12041 10.1111/j.1365-277X.2012.01259.x 10.1002/humu.10035 10.1002/(SICI)1098-1004(199910)14:4<352::AID-HUMU15>3.0.CO;2-D 10.1007/s10545-007-0429-x 10.1007/s00439-013-1358-4 10.1016/j.ymgme.2013.09.003 10.1016/j.ymgme.2010.02.019 10.1023/A:1020108002877 10.1016/j.ymgme.2008.05.004 10.1111/j.1651-2227.2008.00923.x 10.1016/j.ymgme.2005.08.012 10.1542/peds.105.1.e10 10.1016/j.ymgme.2010.01.013 10.1067/mpd.2001.111834 10.1007/s10545-013-9624-0 10.1186/1750-1172-6-44 |
| ContentType | Journal Article |
| Copyright | Martín-Hernández et al.; licensee BioMed Central Ltd. 2014 COPYRIGHT 2014 BioMed Central Ltd. |
| Copyright_xml | – notice: Martín-Hernández et al.; licensee BioMed Central Ltd. 2014 – notice: COPYRIGHT 2014 BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 7X8 5PM |
| DOI | 10.1186/s13023-014-0187-4 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1750-1172 |
| ExternalDocumentID | PMC4258263 A540649369 25433810 10_1186_s13023_014_0187_4 |
| Genre | Multicenter Study Journal Article Observational Study |
| GeographicLocations | Spain |
| GeographicLocations_xml | – name: Spain |
| GroupedDBID | --- 0R~ 123 29N 2WC 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ISR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 7X8 5PM |
| ID | FETCH-LOGICAL-c609t-c3084fa6a6780cbcd509f91e3847669f6de9e7d2cabc6cff333304c629df28f73 |
| IEDL.DBID | M48 |
| ISSN | 1750-1172 |
| IngestDate | Thu Aug 21 18:32:46 EDT 2025 Thu Sep 04 18:26:59 EDT 2025 Tue Jun 17 22:04:36 EDT 2025 Tue Jun 10 21:11:29 EDT 2025 Fri Jun 27 05:35:35 EDT 2025 Mon Jul 21 06:08:50 EDT 2025 Tue Jul 01 02:23:21 EDT 2025 Thu Apr 24 23:01:26 EDT 2025 Sat Sep 06 07:29:00 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Citrullinemia type 1 Argininosuccinate lyase Arginase 1 N-acetylglutamate synthase Argininosuccinate synthetase Argininosuccinic aciduria Carbamoylphosphate synthetase 1 UCDs Urea cycle disorders Ornithine transcarbamylase |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c609t-c3084fa6a6780cbcd509f91e3847669f6de9e7d2cabc6cff333304c629df28f73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://doi.org/10.1186/s13023-014-0187-4 |
| PMID | 25433810 |
| PQID | 1677377262 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4258263 proquest_miscellaneous_1677377262 gale_infotracmisc_A540649369 gale_infotracacademiconefile_A540649369 gale_incontextgauss_ISR_A540649369 pubmed_primary_25433810 crossref_primary_10_1186_s13023_014_0187_4 crossref_citationtrail_10_1186_s13023_014_0187_4 springer_journals_10_1186_s13023_014_0187_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-11-30 |
| PublicationDateYYYYMMDD | 2014-11-30 |
| PublicationDate_xml | – month: 11 year: 2014 text: 2014-11-30 day: 30 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Orphanet journal of rare diseases |
| PublicationTitleAbbrev | Orphanet J Rare Dis |
| PublicationTitleAlternate | Orphanet J Rare Dis |
| PublicationYear | 2014 |
| Publisher | BioMed Central BioMed Central Ltd |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd |
| References | ML Couce (187_CR15) 2009; 70 GM Enns (187_CR19) 2007; 356 J Sander (187_CR12) 2003; 162 PB Acosta (187_CR44) 2005; 86 C Climent (187_CR25) 1999; 4 IK Kim (187_CR21) 2013; 17 M Mavinakere (187_CR38) 2001; 24 S Picca (187_CR17) 2001; 16 C Dionisi-Vici (187_CR4) 2001; 140 S Adam (187_CR33) 2012; 25 J Häberle (187_CR11) 2012; 7 MA García-Pérez (187_CR24) 1995; 95 S Mercimek-Mahmutoglu (187_CR13) 2010; 100 C Climent (187_CR26) 2002; 19 M Tuchman (187_CR36) 1998; 21 PD Stenson (187_CR31) 2014; 133 DA Applegarth (187_CR3) 2000; 105 A Bélanger-Quintana (187_CR30) 2003; 162 187_CR32 M Lindner (187_CR42) 2011; 6 SW Brusilow (187_CR1) 1984; 74 WJ Kleijer (187_CR40) 2002; 25 JA Arranz (187_CR27) 2007; 30 FA Wijburg (187_CR10) 2012 S Adam (187_CR46) 2013; 110 CM Rüegger (187_CR34) 2014; 37 J Haberle (187_CR39) 2002; 110 ML Summar (187_CR7) 2013; 110 T Stevenson (187_CR20) 2009; 14 187_CR35 F Schaefer (187_CR16) 1999; 14 ML Summar (187_CR9) 2008; 97 M Summar (187_CR14) 2001; 138 M Tuchman (187_CR22) 2008; 94 M Tuchman (187_CR37) 2002; 19 MA Vilaseca (187_CR28) 2001; 74 P Keskinen (187_CR6) 2008; 97 RH Singh (187_CR45) 2007; 30 S Brusilow (187_CR2) 2001 187_CR43 M Hernández (187_CR29) 2002 S Sanderson (187_CR5) 2006; 91 C Ficicioglu (187_CR41) 2009; 98 JM Saudubray (187_CR8) 2002; 7 S Kölker (187_CR23) 2011; 34 F Scaglia (187_CR18) 2010; 100 11793483 - Hum Mutat. 2002 Feb;19(2):185-6 7860064 - Hum Genet. 1995 Feb;95(2):183-6 11953730 - J Pediatr. 2002 Mar;140(3):321-7 19635676 - Mol Genet Metab. 2009 Nov;98(3):273-7 17334707 - J Inherit Metab Dis. 2007 Apr;30(2):217-26 19217576 - An Pediatr (Barc). 2009 Feb;70(2):183-8 11768581 - J Inherit Metab Dis. 2001 Nov;24(6):614-22 20299258 - Mol Genet Metab. 2010;100 Suppl 1:S72-6 22594780 - J Hum Nutr Diet. 2012 Aug;25(4):398-404 10328469 - Nephrol Dial Transplant. 1999 Apr;14(4):910-8 20236848 - Mol Genet Metab. 2010 May;100(1):24-8 21689452 - Orphanet J Rare Dis. 2011;6:44 19671092 - Pediatr Transplant. 2010 Mar;14(2):268-75 11148543 - J Pediatr. 2001 Jan;138(1 Suppl):S1-5 23347504 - Pediatr Transplant. 2013 Mar;17(2):158-67 11793468 - Hum Mutat. 2002 Feb;19(2):93-107 22642880 - Orphanet J Rare Dis. 2012;7:32 24113687 - Mol Genet Metab. 2013 Dec;110(4):439-45 16260164 - Mol Genet Metab. 2005 Dec;86(4):448-55 18562231 - Mol Genet Metab. 2008 Aug;94(4):397-402 6511918 - J Clin Invest. 1984 Dec;74(6):2144-8 18616627 - Acta Paediatr. 2008 Oct;97(10):1412-9 16690699 - Arch Dis Child. 2006 Nov;91(11):896-9 23780642 - J Inherit Metab Dis. 2014 Jan;37(1):21-30 18330140 - World Health Organ Tech Rep Ser. 2007;(935):1-265, back cover 12942317 - Eur J Pediatr. 2003 Nov;162(11):773-5 10502831 - Hum Mutat. 1999 Oct;14(4):352-3 18647279 - Acta Paediatr. 2008 Oct;97(10):1420-5 24077912 - Hum Genet. 2014 Jan;133(1):1-9 23972786 - Mol Genet Metab. 2013 Sep-Oct;110(1-2):179-80 18034368 - J Inherit Metab Dis. 2007 Nov;30(6):880-7 9686344 - J Inherit Metab Dis. 1998;21 Suppl 1:40-58 10617747 - Pediatrics. 2000 Jan;105(1):e10 11941481 - Hum Genet. 2002 Apr;110(4):327-33 12069534 - Semin Neonatol. 2002 Feb;7(1):3-15 12408190 - J Inherit Metab Dis. 2002 Sep;25(5):399-410 11685590 - Pediatr Nephrol. 2001 Nov;16(11):862-7 12684898 - Eur J Pediatr. 2003 Jun;162(6):417-20 11708871 - Mol Genet Metab. 2001 Nov;74(3):396-8 17538087 - N Engl J Med. 2007 May 31;356(22):2282-92 11148547 - J Pediatr. 2001 Jan;138(1 Suppl):S30-9 |
| References_xml | – volume: 98 start-page: 273 year: 2009 ident: 187_CR41 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2009.06.011 – volume: 14 start-page: 910 year: 1999 ident: 187_CR16 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/14.4.910 – volume: 24 start-page: 614 year: 2001 ident: 187_CR38 publication-title: J Inherit Metab Dis doi: 10.1023/A:1012726207870 – volume: 110 start-page: 327 year: 2002 ident: 187_CR39 publication-title: Hum Genet doi: 10.1007/s00439-002-0686-6 – volume: 74 start-page: 396 year: 2001 ident: 187_CR28 publication-title: Mol Genet Metab doi: 10.1006/mgme.2001.3221 – volume: 74 start-page: 2144 year: 1984 ident: 187_CR1 publication-title: J Clin Invest doi: 10.1172/JCI111640 – volume: 19 start-page: 185 year: 2002 ident: 187_CR26 publication-title: Hum Mutat doi: 10.1002/humu.9011 – volume: 21 start-page: 40 issue: Suppl 1 year: 1998 ident: 187_CR36 publication-title: J Inherit Metab Dis doi: 10.1023/A:1005353407220 – volume: 110 start-page: 179 year: 2013 ident: 187_CR7 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2013.07.008 – volume: 14 start-page: 268 year: 2009 ident: 187_CR20 publication-title: Pediatr Transplant doi: 10.1111/j.1399-3046.2009.01228.x – volume: 91 start-page: 896 year: 2006 ident: 187_CR5 publication-title: Arch Dis Child doi: 10.1136/adc.2005.091637 – volume: 16 start-page: 862 year: 2001 ident: 187_CR17 publication-title: Pediatr Nephrol doi: 10.1007/s004670100702 – volume: 97 start-page: 1420 year: 2008 ident: 187_CR9 publication-title: Acta Paediatr doi: 10.1111/j.1651-2227.2008.00952.x – volume: 7 start-page: 32 year: 2012 ident: 187_CR11 publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-7-32 – volume: 162 start-page: 417 year: 2003 ident: 187_CR12 publication-title: Eur J Pediatr doi: 10.1007/s00431-003-1177-z – volume: 70 start-page: 183 year: 2009 ident: 187_CR15 publication-title: An Pediatr (Barc) doi: 10.1016/j.anpedi.2008.10.007 – ident: 187_CR43 doi: 10.1067/mpd.2001.111830 – ident: 187_CR35 – volume: 30 start-page: 880 year: 2007 ident: 187_CR45 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-007-0718-4 – start-page: 1909 volume-title: The Metabolic and Molecular Bases of Inherited Diseases year: 2001 ident: 187_CR2 – volume: 34 start-page: s93 year: 2011 ident: 187_CR23 publication-title: J Inher Matabolic Dis doi: 10.1007/s10545-010-9151-1 – volume: 356 start-page: 2282 year: 2007 ident: 187_CR19 publication-title: N Engl J Med doi: 10.1056/NEJMoa066596 – volume: 7 start-page: 3 year: 2002 ident: 187_CR8 publication-title: Semin Neonatol doi: 10.1053/siny.2001.0083 – volume: 162 start-page: 773 year: 2003 ident: 187_CR30 publication-title: Eur J Pediatr doi: 10.1007/s00431-002-1126-2 – start-page: 297 volume-title: Inborn Metabolic Diseases, Diagnosis and Treatment year: 2012 ident: 187_CR10 doi: 10.1007/978-3-642-15720-2_20 – ident: 187_CR32 – volume: 140 start-page: 321 year: 2001 ident: 187_CR4 publication-title: J Pediatr doi: 10.1067/mpd.2002.122394 – volume: 17 start-page: 158 year: 2013 ident: 187_CR21 publication-title: Pediatr Transplant doi: 10.1111/petr.12041 – volume: 25 start-page: 398 year: 2012 ident: 187_CR33 publication-title: J Hum Nutr Diet doi: 10.1111/j.1365-277X.2012.01259.x – volume: 19 start-page: 93 year: 2002 ident: 187_CR37 publication-title: Hum Mutat doi: 10.1002/humu.10035 – volume: 4 start-page: 352 year: 1999 ident: 187_CR25 publication-title: Hum Mutat doi: 10.1002/(SICI)1098-1004(199910)14:4<352::AID-HUMU15>3.0.CO;2-D – volume: 30 start-page: 217 year: 2007 ident: 187_CR27 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-007-0429-x – volume: 133 start-page: 1 year: 2014 ident: 187_CR31 publication-title: Hum Genet doi: 10.1007/s00439-013-1358-4 – volume: 110 start-page: 439 year: 2013 ident: 187_CR46 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2013.09.003 – volume: 100 start-page: S72 issue: Suppl 1 year: 2010 ident: 187_CR18 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2010.02.019 – volume: 25 start-page: 399 year: 2002 ident: 187_CR40 publication-title: J Inherit Metab Dis doi: 10.1023/A:1020108002877 – volume-title: Instituto de Investigación sobre Crecimiento y Desarrollo. Fundación F. Orbegozo. Bilbao. 3ª Edición year: 2002 ident: 187_CR29 – volume: 94 start-page: 397 year: 2008 ident: 187_CR22 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2008.05.004 – volume: 97 start-page: 1412 year: 2008 ident: 187_CR6 publication-title: Acta Paediatr doi: 10.1111/j.1651-2227.2008.00923.x – volume: 86 start-page: 448 year: 2005 ident: 187_CR44 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2005.08.012 – volume: 95 start-page: 183 year: 1995 ident: 187_CR24 publication-title: Hum Genet – volume: 105 start-page: e10 issue: 1 year: 2000 ident: 187_CR3 publication-title: Pediatrics doi: 10.1542/peds.105.1.e10 – volume: 100 start-page: 24 year: 2010 ident: 187_CR13 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2010.01.013 – volume: 138 start-page: S30 year: 2001 ident: 187_CR14 publication-title: J Pediatr doi: 10.1067/mpd.2001.111834 – volume: 37 start-page: 21 year: 2014 ident: 187_CR34 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-013-9624-0 – volume: 6 start-page: 44 year: 2011 ident: 187_CR42 publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-6-44 – reference: 21689452 - Orphanet J Rare Dis. 2011;6:44 – reference: 10617747 - Pediatrics. 2000 Jan;105(1):e10 – reference: 11768581 - J Inherit Metab Dis. 2001 Nov;24(6):614-22 – reference: 18330140 - World Health Organ Tech Rep Ser. 2007;(935):1-265, back cover – reference: 12942317 - Eur J Pediatr. 2003 Nov;162(11):773-5 – reference: 11793483 - Hum Mutat. 2002 Feb;19(2):185-6 – reference: 7860064 - Hum Genet. 1995 Feb;95(2):183-6 – reference: 9686344 - J Inherit Metab Dis. 1998;21 Suppl 1:40-58 – reference: 23347504 - Pediatr Transplant. 2013 Mar;17(2):158-67 – reference: 11148543 - J Pediatr. 2001 Jan;138(1 Suppl):S1-5 – reference: 16260164 - Mol Genet Metab. 2005 Dec;86(4):448-55 – reference: 12069534 - Semin Neonatol. 2002 Feb;7(1):3-15 – reference: 18562231 - Mol Genet Metab. 2008 Aug;94(4):397-402 – reference: 19671092 - Pediatr Transplant. 2010 Mar;14(2):268-75 – reference: 20236848 - Mol Genet Metab. 2010 May;100(1):24-8 – reference: 23780642 - J Inherit Metab Dis. 2014 Jan;37(1):21-30 – reference: 11953730 - J Pediatr. 2002 Mar;140(3):321-7 – reference: 20299258 - Mol Genet Metab. 2010;100 Suppl 1:S72-6 – reference: 10328469 - Nephrol Dial Transplant. 1999 Apr;14(4):910-8 – reference: 19635676 - Mol Genet Metab. 2009 Nov;98(3):273-7 – reference: 11941481 - Hum Genet. 2002 Apr;110(4):327-33 – reference: 17538087 - N Engl J Med. 2007 May 31;356(22):2282-92 – reference: 22594780 - J Hum Nutr Diet. 2012 Aug;25(4):398-404 – reference: 11685590 - Pediatr Nephrol. 2001 Nov;16(11):862-7 – reference: 10502831 - Hum Mutat. 1999 Oct;14(4):352-3 – reference: 24077912 - Hum Genet. 2014 Jan;133(1):1-9 – reference: 12408190 - J Inherit Metab Dis. 2002 Sep;25(5):399-410 – reference: 11708871 - Mol Genet Metab. 2001 Nov;74(3):396-8 – reference: 22642880 - Orphanet J Rare Dis. 2012;7:32 – reference: 12684898 - Eur J Pediatr. 2003 Jun;162(6):417-20 – reference: 19217576 - An Pediatr (Barc). 2009 Feb;70(2):183-8 – reference: 11148547 - J Pediatr. 2001 Jan;138(1 Suppl):S30-9 – reference: 18616627 - Acta Paediatr. 2008 Oct;97(10):1412-9 – reference: 23972786 - Mol Genet Metab. 2013 Sep-Oct;110(1-2):179-80 – reference: 6511918 - J Clin Invest. 1984 Dec;74(6):2144-8 – reference: 18034368 - J Inherit Metab Dis. 2007 Nov;30(6):880-7 – reference: 18647279 - Acta Paediatr. 2008 Oct;97(10):1420-5 – reference: 11793468 - Hum Mutat. 2002 Feb;19(2):93-107 – reference: 16690699 - Arch Dis Child. 2006 Nov;91(11):896-9 – reference: 17334707 - J Inherit Metab Dis. 2007 Apr;30(2):217-26 – reference: 24113687 - Mol Genet Metab. 2013 Dec;110(4):439-45 |
| SSID | ssj0045308 |
| Score | 2.2680411 |
| Snippet | Background
Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe... Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the... Background Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 187 |
| SubjectTerms | Adolescent Adult Analysis Arginine Care and treatment Child Child, Preschool Cross-Sectional Studies Female Human Genetics Humans Infant Infants (Newborn) Inherited metabolic diseases Ligases Male Medicine Medicine & Public Health Pharmacology/Toxicology Spain - epidemiology Urea Cycle Disorders, Inborn - diagnosis Urea Cycle Disorders, Inborn - epidemiology Urea Cycle Disorders, Inborn - genetics Young Adult |
| SummonAdditionalLinks | – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA96gvgifl-9U6IIglpsmzRtfTsWj1M4HzwX7i0k08RbONLD7j74399MNrtcFxV8zrRN5zOTmfzC2JtG2M5bgr40IHLZS5lbjGw5NL5wtlV9Hfd0T7-pk7n8el6fJ7BoOgtzs35fturjSIU16vihXgm0B3mb3alLocgGZ2q2cbqyFkWbipZ_fGwSdnad743os9sZuVMejVHn-AG7n5aL_Ggt34fslguP2N3TVBB_zPo5Lvo4_MZB3icgzZEvAj-7wpT_EzeBD3a78WouP_A4v3yMHVj0ahN6HrsK42QWwCPgLB88xxSKAwa58QmbH3_-MTvJ08UJOaiiW-aAzJDeKIORqAALxHDflU5gKFKq86p3nWv6CowFBd4LQbsaoKqu91XrG_GU7YUhuH3GO4Lfsb703oBUAlNvb13R10aV0EopMlZs-KohoYrT5RaXOmYXrdJrUWgUhSZRaJmxd9tHrtaQGv8ifk3C0gRVEagX5qdZjaP-cvZdH-FiU0m6kDBjbxORH_DjYNLRAvwFQreaUB5OKNGWYDL8aqMTmoaoAS24YTXqUjWNwExEVRl7ttaR7eQJT4CA0jLWTLRnS0AQ3tORsLiIUN7oMTG_Qy6-3-iZTj5k_DtPnv8X9QG7V5EdRLjKQ7a3_LVyL3AhtbQvowldA8yxFVA priority: 102 providerName: Springer Nature |
| Title | Urea cycle disorders in Spain: an observational, cross-sectional and multicentric study of 104 cases |
| URI | https://link.springer.com/article/10.1186/s13023-014-0187-4 https://www.ncbi.nlm.nih.gov/pubmed/25433810 https://www.proquest.com/docview/1677377262 https://pubmed.ncbi.nlm.nih.gov/PMC4258263 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ti9NAEB7uBcQv4rvVs6wiCGrONNluEkGkljvOQg-5Wui3ZXeT1ULZnJcWvH_vzDYJppyCnwrZSbqdncmzszN9BuBVEuvMaqK-VCYOeM55oBHZApPYsNCpyIf-THd6Ls7mfLIYLvagaW9VK7C6MbSjflLzq9Xxr5_Xn9DhP3qHT8X7ipJvVBVE9RToM3wfDhGYBMViU94mFfgw9g3qEDDDYIDAXSc5b3xEB6Z2X9Z_oNVuJeVOOtWj1OlduFNvL9loaw_3YK9w9-HWtE6gP4B8jptEZq5xkOU18WbFlo7NLtXSfWDKsVK3B7Vq9Y75-QWVr9iiRyuXM1-F6CezNMwT1LLSMgy5mEFQrB7C_PTk2_gsqBstBEaE2TowqBhulVCIXKHRhhbIZoMiRugSIrMiL7IiySOjtBHG2jimUxAjoiy3UWqT-BEcuNIVT4BlRNej7cBaZbiIMVS3ugjzoRIDk3Ie9yBs9CpNzUJOzTBW0kcjqZDbpZC4FJKWQvIevGlvudxScPxL-CUtliRqC0e1M9_Vpqrkl9mFHOHmVHBqYNiD17WQLfHLjar_ioA_gdiwOpJHHUn0PdMZftHYhKQhKlhzRbmpJFpfEmPkIqIePN7aSDt54h8gYrUeJB3raQWI8rs74pY_PPU3vmExHkQtvm3sTDYu83edPP0fBT6D2xG5gWe3PIKD9dWmeI77rrXuw36ySPpwOBpNZhP8_Hxy_vUCr47FuO_PMvre334DV-krJg |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSMAF8W6ggEFISEDUJPY6CbeqotpCtwfalXqz_GxXqpyK7B767zvj9a6aFSBx9iRx5unxjD8T8rFmuvUaoS-VYTm3nOcaIltual843Qg7inu6k2MxnvIfZ6OzBBaNZ2Fu1-_LRuz2WFjDjh_slQB74HfJPV5C6oN1WbG_crp8xIomFS3_-Ngg7Gw631vRZ7MzcqM8GqPOwWPyKC0X6d5Svk_IHReekvuTVBB_RuwUFn3UXMMgtQlIs6ezQE-uIOX_RlWgnV5vvKrLrzTOL-9jBxa-WgVLY1dhnMzM0Ag4SztPIYWiBoJc_5xMD76f7o_zdHFCbkTRznMDzOBeCQWRqDDaIMN9WzoGoUiI1gvrWlfbyihthPGeMdzVMKJqra8aX7MXZCt0wW0T2iL8jval98pwwSD19toVdqREaRrOWUaKFV-lSajieLnFpYzZRSPkUhQSRCFRFJJn5PP6kaslpMa_iD-gsCRCVQTshTlXi76Xhye_5B4sNgXHCwkz8ikR-Q4-blQ6WgC_gOhWA8qdASXYkhkMv1_phMQhbEALrlv0shR1zSATEVVGXi51ZD15xBNAoLSM1APtWRMghPdwJMwuIpQ3eEzI74CLX1Z6JpMP6f_Ok1f_Rf2OPBifTo7k0eHxz9fkYYU2EaErd8jW_PfCvYFF1Vy_jeZ0Axp4GEc |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA96wuGL-G311CiCoJbrNtm09e1YXe7UO8Rz4d5CPhpdONLF7D743zuTpotdVPA50zbNfGcmvxDyomK6cRqhL5VhObec5xo8W24qV7S6FnYa93RPz8Txgn-4mF6ke07D0O0-lCT7Mw2I0uTXhyvrehWvxWHAchv2AWEHBWgJv0quQaJSoFjPxGwwxXzKijqVMv_42MgZ7Zrk33zSbr_kTtE0-qL5TXIjBZH0qOf6LXKl9bfJ_mkqk98hdgGhIDU_YZDaBK8Z6NLT85Va-rdUedrp7XasunxD4_zyEPuy8NXKWxp7DeNkloZGGFraOQqJFTXg-sJdspi__zo7ztN1CrkRRbPODSwGd0oo8E-F0QbZ4JpJy8BBCdE4YdumrWxplDbCOMcY7nUYUTbWlbWr2D2y5zvfPiC0QVAe7SbOKcMFg4Tc6bawUyUmpuacZaQY1lWahDWOV15cyphz1EL2rJDAComskDwjr7aPrHqgjX8RP0dmSQSw8Ngh801tQpAn51_kEYSgguM1hRl5mYhcBx83Kh04gF9AzKsR5cGIEjTMjIafDTIhcQjb0nzbbYKciKpikJ-IMiP3exnZTh5RBhA-LSPVSHq2BAjsPR7xy-8R4BvsKGR9sIqvBzmTybKEv6_Jw_-ifkr2P7-by08nZx8fkeslqkTEszwge-sfm_YxRFpr_SRq0y_ZeSCO |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Urea+cycle+disorders+in+Spain%3A+an+observational%2C+cross-sectional+and+multicentric+study+of+104+cases&rft.jtitle=Orphanet+journal+of+rare+diseases&rft.au=Mart%C3%ADn-Hern%C3%A1ndez%2C+Elena&rft.au=Ald%C3%A1miz-Echevarr%C3%ADa%2C+Luis&rft.au=Castej%C3%B3n-Ponce%2C+Esperanza&rft.au=Pedr%C3%B3n-Giner%2C+Consuelo&rft.date=2014-11-30&rft.issn=1750-1172&rft.eissn=1750-1172&rft.volume=9&rft.issue=1&rft_id=info:doi/10.1186%2Fs13023-014-0187-4&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13023_014_0187_4 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1172&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1172&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1172&client=summon |